Triplet chemotherapy for malignant pericardial mesothelioma: A case report

Japanese Journal of Clinical Oncology

Volumn 36, Issue 4, 2006, Pages 245-248

  Maruyama, Riichiroh ^a   Sakai, Maki ^a   Nakamura, Tomomi ^a   Suemitsu, Ryuichi ^a   Okamoto, Tatsuro ^a   Wataya, Hiroshi ^a   Nishiyama, Kenichi ^a   Kamei, Toshiaki ^b   Ichinose, Yukito ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b Yamaguchi Grand Medical Center   (Japan)

Author keywords

Long term survival; Malignant pericardial mesothelioma; Triplet chemotherapy

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE; TUMOR MARKER;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CYTOPATHOLOGY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; FEMALE; HEART TAMPONADE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; NEUTROPENIA; PERICARDIAL DISEASE; PERICARDIAL EFFUSION; SURGICAL DRAINAGE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DRAINAGE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART NEOPLASMS; HUMANS; MESOTHELIOMA; MIDDLE AGED; NEUTROPENIA; PERICARDIAL EFFUSION; REMISSION INDUCTION; SURVIVORS; VINBLASTINE;

EID: 33745700678     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl003     Document Type: Article

References (13)

1. Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare of Japan. Vital Statistics of Japan 2001. Tokyo: Health and Welfare Statistics Association 2001.
2. Murai Y. Malignant mesothelioma in Japan: Analysis of registered autopsy cases. Arch Environ Health 2001;56:84-8.
3. Maruyama R, Shoji F, Okamoto T, Miyamoto T, Miyake T, Nakamura T, et al. Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma. Jpn J Clin Oncol 2005;35:433-8.
4. Pier-Giacomo B. Immunohistochemistry. In: Carbone M, editor. Malignant Mesothelioma. Advances in Pathogenesis, Diagnosis, and Translational Therapies. New York: Springer Science+Business Media, Inc., 2005;490-507.
5. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108:1122-8.
6. Chahinian AP. Clinical presentation and natural history of mesothelioma: pleural and pericardial. In: Carbone M, editor. Malignant Mesothelioma. Advances in Pathogenesis, Diagnosis, and Translational Therapies. New York: Springer Science+Business Media, Inc., 2005;380-90.
7. Kaul TK, Fields BL, Kahn DR. Primary malignant pericardial mesothelioma: a case report and review. J Cardiovasc Surg (Torino) 1994;35:261-7.
8. Nambiar CA, Tareif HE, Kishore KU, Ravindran J, Banerjee AK. Primary pericardial mesothelioma: One-year event-free survival. Am Heart J 1992;124:802-3.
9. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 1999;17:25-30.
10. Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002;87:491-6.
11. van Haarst JM, Baas P, Manegold C, Schouwink JH, Burgers JA, de Bruin HG, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002;86: 342-5.
12. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000;18:3912-7.
13. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffle P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.